Sihuan Pharma has begun a US-based Phase I clinical trial of pirotinib, a novel pan-HER inhibitor for patients with lung and gastric cancers. Pirotinib, which is the first Sihuan product to be tested in the US, is a second-gen HER inhibitor whose preclinical studies showed unique profiles in pharmacology, pharmacokinetics and toxicology. The drug received CFDA approval to begin a China trial in 2013.
Help employers find you! Check out all the jobs and post your resume.
